Current Ratio
13.19x
Period-end balance · Through 31 Dec 2023
YoY relative change: -1.9%
Kinnate Biopharma Inc. financial metrics
Period Q1 2024 · Filed 28 Mar 2024
Key metrics snapshot
Debt-to-equity
0.1x
Period-end balance · Through 31 Dec 2023
YoY relative change: +39%
Financial Health
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
13.19x
Period-end balance · 31 Dec 2023
|
-1.9% |
| Debt-to-equity |
0.1x
Period-end balance · 31 Dec 2023
|
+39% |
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
47,225,312
Period-end balance · 20 Mar 2024
|
+1.4% |
Comparisons, sources and research notes
Sources and sharing
Kinnate Biopharma Inc. Financial Facts
- Context
- Latest metrics period: Q1 2024
- Latest reported value
- Current Ratio 13.19x
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q1 2024
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q1 2024.
- Most recent SEC facts end date on this page: 20 Mar 2024.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for Kinnate Biopharma Inc.
Latest financial period: Q4 2023. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
28 Mar 2024
Page type
Company facts
Latest period
Q1 2024
SEC-backed company facts were refreshed from filings filed on 28 Mar 2024.
Benchmark Context
How Current Ratio compares
Current Ratio is down about 1.9% versus the comparable prior period.
Compared with
Compared with Kinnate Biopharma Inc.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Current Ratio already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q1 2024.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
Filing notes and source
Key facts
- Kinnate Biopharma Inc. financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q1 2024.
- Headline metric: Current Ratio 13.19x.
Change
- Current Ratio YoY relative change: -1.9%.
- Most recent SEC facts end date: 20 Mar 2024.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2024-03-20) highlights Current Ratio 13.19x and Debt-to-equity 0.1x.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
No market comparison
Low confidence
USD inputs only. Cash and complete debt must share the latest balance date. Missing balances are unknown, never zero; equity value and market EV remain unavailable until both are verified.
Fair value per share
n/a
Market price
n/a
PEG ratio
n/a
Enterprise value
-$1.46B
Equity value
n/a
DCF fair value scenarios
Bear
n/a
- Growth
- 1%
- Discount
- 11%
- Terminal
- 2%
Base
n/a
- Growth
- 4%
- Discount
- 10%
- Terminal
- 2.5%
Bull
n/a
- Growth
- 7%
- Discount
- 9%
- Terminal
- 3%
Base growth: DCF Growth Assumption.
Key valuation metrics
EV/Revenue
n/a
Market price market EV / SEC revenue
Market enterprise value is unavailable
EV/EBITDA
n/a
Market price market EV / SEC EBITDA
Market enterprise value is unavailable
P/E
n/a
Market price market price / SEC EPS
Market cap is unavailable
P/S
n/a
Market price market cap / SEC revenue
Market cap is unavailable
P/B
n/a
Market price market cap / SEC equity
Market cap is unavailable
PEG
n/a
P/E / DCF Growth Assumption
P/e or positive growth is unavailable
Core assumptions
- Projection
- 5 years
- FCF growth
- 4%
- Discount rate
- 10%
- Terminal growth
- 2.5%
SEC fact inputs
- DCF base FCF
- -$100.04M
- Trailing SEC FCF
- Reported FCF
- -$100.04M
- Net income
- -$112.65M
- EBITDA
- -$120.38M
- Cash
- $57M
- Debt
- n/a
- Equity
- $159.33M
- Shares
- 46,575,378
Input periods, units and SEC sources
Equity value = DCF enterprise value + cash − debt. Cash flow uses matching annual or trailing-12-month periods.
- Operating cash flow: -100,043,000.0 USD · through 2023-12-31 · reported annual SEC source
- Capital expenditures: 0.0 USD · through 2023-12-31 · reported annual SEC source
- Cash and equivalents: 56,998,000.0 USD · through 2023-12-31 SEC source
- Debt: unavailable on a verified comparable basis
Data confidence notes
- Debt unavailable: no complete usd debt balance at the latest balance date
- Dcf base free cash flow: trailing free cash flow is not positive
- Dcf confidence is low for this sec-only free cash flow estimate
- Ticker missing for issuer
- Debt missing: equity value and market ev unavailable
- Base free cash flow is negative; dcf output is mechanically computed but high risk
- Peg unavailable: market price is missing
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
53.7/100
Caution Confidence low
Financial Health
- Current Ratio
- 13.19x
- Debt to Equity
- 0.1x
Strengths
Debt-to-equity
Watchpoints
Current Ratio
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first